Home

Senores Pharmaceuticals Ltd EPS

Image

Senores Pharmaceuticals Ltd

NSE: SENORES

EPS

₹ 6.84

Last updated on: Mar 12, 2025

Key Highlights

  • The Earning per Share of Senores Pharmaceuticals Ltd is ₹ 6.84 as of 12 Mar 25 .
  • The earning per share of Senores Pharmaceuticals Ltd changed from ₹ 4.01 to ₹ 5.04 over 3 quarters. This represents a CAGR of 35.64% .

Historical Earning per Share of Senores Pharmaceuticals Ltd

No data available

* All values are in

Company Fundamentals for Senores Pharmaceuticals Ltd

Market Cap

2,654 Cr

EPS

6.8

P/E Ratio (TTM)

84.3

P/B Ratio (TTM)

3.5

Day’s High

579.95

Day’s Low

553.65

DTE

1.3

ROE

15.4

52 Week High

644.4

52 Week Low

440.0

ROCE

7.4

Market Price of Senores Pharmaceuticals Ltd

1M

1Y

3Y

5Y

Monitoring Senores Pharmaceuticals Ltd share price can help you stay informed about potential market shifts and opportunities. *All values are in Rupees.

Last Ten Days Market Price

Date
leftPrice (₹)right
12 Mar 2025576.35
11 Mar 2025551.2
10 Mar 2025548.75
07 Mar 2025566.1
06 Mar 2025593.75
05 Mar 2025596.1
04 Mar 2025562.2
03 Mar 2025530.4
28 Feb 2025543.75
27 Feb 2025566.7

BlinkX Score for Senores Pharmaceuticals Ltd

Asset Value vs Market Value of Senores Pharmaceuticals Ltd

Market Value

2,654

Asset Value

Value addition

9.0 X

266

* All values are in ₹ crores

Competitive Comparison of EPS

Company
leftMarket Capright
Senores Pharmaceuticals Ltd2654
Sun Pharmaceuticals Industries Ltd402213
Divis Laboratories Ltd150403
Cipla Ltd117415
Torrent Pharmaceuticals Ltd104786
Dr Reddys Laboratories Ltd92227

Historical Market Cap of Senores Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Revenue of Senores Pharmaceuticals Ltd

No data available

* All values are in crore

Historical EBITDA of Senores Pharmaceuticals Ltd

No data available

* All values are in crore

Historical Net Profit of Senores Pharmaceuticals Ltd

No data available

* All values are in crore

Dividend Payout Over Time

No data available

Senores Pharmaceuticals Ltd News Hub

Senores Pharma spurts as PAT jumps to Rs 16 cr in Q3 FY25

Profit before tax stood at Rs 20.48 crore in the December 2024 quarter, up 99.61% from Rs 10.26 cror

Read more

23 Jan 25

Senores Pharma gets final approval for Metoprolol Tartrate and Hydrochlorothiazide tablets

Metoprolol Tartrate and Hydrochlorothiazide Tablet is the combination tablet of metoprolol tartrate,

Read more

10 Jan 25

Senores Pharmaceuticals IPO subscribed 93.41 times

The initial public offer (IPO) of Senores Pharmaceuticals received bids for 79,72,30,918 shares as a

Read more

24 Dec 24

Senores Pharmaceuticals receives USFDA approval for Metoprolol Tartrate and Hydrochlorothiazide Tablet

Senores Pharmaceuticals has received final approval from the United States Food and Drug Administrat

Read more

10 Jan 25

Document

Annual Reports

N/A

dropdown
download

Credit Ratings

N/A

dropdown
download

Concalls

Data not available

FAQs for EPS of Senores Pharmaceuticals Ltd

What is the EPS of Senores Pharmaceuticals Ltd stock?

The Earnings Per Share (EPS) of Senores Pharmaceuticals Ltd is 6.84. An EPS is the amount of net income attributed to each share of a common stock.

How is Senores Pharmaceuticals Ltd EPS calculated?

The EPS of Senores Pharmaceuticals Ltd is calculated by dividing the net income by the number of outstanding shares. The formula is EPS = (Net Income - Dividends on Preferred Stock) / Average Outstanding Shares.

How often does Senores Pharmaceuticals Ltd report its EPS?

Senores Pharmaceuticals Ltd typically reports its EPS quarterly and annually, in conjunction with its financial statements and earnings reports.

What factors can influence Senores Pharmaceuticals Ltd EPS?

Factors that influence the EPS of Senores Pharmaceuticals Ltd include revenue changes, cost fluctuations, operational efficiency, tax rates, and one-time gains or losses.

Can Senores Pharmaceuticals Ltd EPS growth indicate future performance?

Yes, consistent growth in Senores Pharmaceuticals Ltd EPS can suggest strong financial health and effective management, potentially indicating positive future performance.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions